

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Alan Crossman et al. Int'l Appln. No.: PCT/GB03/003801  
U.S. Serial No.: To be assigned Int'l Filing Date: September 1, 2003  
Filed: Herewith Docket: 184.5USWO  
Title: TREATMENT OF DYSKINESIA

**CERTIFICATE OF MAILING UNDER 37 CFR 1.10****'Express Mail' mailing label number: EV 329956507 US****Date of Deposit: March 10, 2005**

I hereby certify that this paper or fee is being deposited with the United States Postal Service 'Express Mail Post Office To Addressee' service under 37 CFR 1.10 and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

By: Barbara Senty  
Name: Barbara Senty

**INFORMATION DISCLOSURE STATEMENT(37 C.F.R. §1.97(b))**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted within 3-months of the filing date of the above-identified application. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. §1.98(a)(2), a copy of the International Search Report and a copy of each foreign patent document and each non-patent document listed on the enclosed Form 1449 is provided.

10/527761

DT19 PCT/PTO 10 MAR 2005

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§.

102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art". Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please direct any response or inquiry to the below-signed attorney at (310) 641-8797.

Respectfully submitted,

GATES & COOPER LLP  
Attorneys for Applicant(s)

Howard Hughes Center  
6701 Center Drive West, Suite 1050  
Los Angeles, California 90045  
(310) 641-8797

Date: March 10, 2005

By: \_\_\_\_\_  
Name: William J. Wood  
Reg. No.: 42,236

WJW/bjs

<b>Form 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b> <b>IN AN APPLICATION</b>	Docket Number: 184.5USWO		Int'l Appln No.: PCT/GB03/003801
	Int'l Filing Date: 1 Sept 2003		
	Applicant: Alan Crossman et al.		
	Filing Date: Herewith	Group Art Unit: To be assigned	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	

  

FOREIGN PATENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO00/61138	10/19/00	PCT				
	WO02/064085	08/22/02	PCT				

  

NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Abuzzahab et al., "Control of Tourette's Syndrome with Topiramate", American Journal of Psychiatry, Vol. 158, No. 6, June 2001, pg. 968, XP009022623.
		Abuzzahab et al., "Topiramate for Clozapine-Induced Seizures", American Journal of Psychiatry, American Psychiatric Association, Washington, D.C., Vol. 158, No. 6, June 2001, pp. 968-969, XP001095768.
		Coppola et al., "Topiramate as Add-On Drug in Severe Myoclonic Epilepsy in Infancy: An Italian Multicenter Open Trial", Epilepsy Research, Vol. 49, No. 1, March 2002, pp. 45-48, XP002264038.
		Dursun et al., "Clozapine Weight Gain, Plus Topiramate Weight Loss", Canadian Journal of Psychiatry, Revue Canadienne de Psychiatrie, Canadian Psychiatric Association, Ottawa, CA, Vol. 45, No. 2, March 2000, pg. 198, XP001097327.
		Kellett et al., "Topiramate in Clinical Practice: First Year's Postlicensing Experience in a Specialist Epilepsy Clinic", Journal of Neurology Neurosurgery and Psychiatry, Vol. 66, No. 6, June 1999, pp. 759-763, XP002264039.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	